ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Perspective: Emerging challenges for a future ADNI.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A multiverse analysis of the logical memory test and plasma biomarkers of Alzheimer's disease.Cortex; a journal devoted to the study of the nervous system and behavior · 2026Article
- History of Alzheimer's Disease Research Centers: From inception in 1984 to evolution beyond 2025.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Perspective: Emerging challenges for a future ADNI.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the last two decades, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has significantly advanced our understanding, technologies, and methods for detecting and diagnosing Alzheimer's disease and related dementias. This perspective proposes repurposing ADNI to address emerging research and healthcare challenges. The focus would shift toward early detection of cognitive impairment, discovering new interventions, evaluating non-pharmacological treatments, adopting a public health approach, and enrolling a diverse international cohort. Key elements of this new model include emphasizing vascular-metabolic factors, leveraging biomarkers, and enhancing computational capabilities. By reimagining ADNI's mission and framework, the initiative may be better poised to tackle the evolving complexities of dementia research and improve patient outcomes through a more comprehensive, multidisciplinary approach. HIGHLIGHTS: ADNI should be repurposed for early detection and intervention in cognitive decline. This would emphasize vascular-metabolic factors and biomarkers in dementia research. It advocates for non-pharmacological evaluations and a public health approach. It promotes international cohort studies and enhanced computational capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.